Corient Private Wealth
ALT icon

Corient Private Wealth’s Altimmune ALT Stock Holding History

Corient Private Wealth’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$94.1K Buy
+30,553
New +$130K ﹤0.01% 2699

Other funds holding ALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Corient Private Wealth's ALT Position: Q1 2026 in Review

Corient Private Wealth opened a new position in Altimmune (ALT) in Q1 2026: 30,553 shares worth $94.1K. The stake represents ﹤0.01% of the portfolio and ranks #2699 among its holdings.

173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

  • Corient Private Wealth held 30,553 shares of Altimmune worth $94.1K as of Q1 2026.
  • Altimmune was a new Corient Private Wealth position in Q1 2026.
  • Altimmune made up ﹤0.01% of Corient Private Wealth's portfolio in Q1 2026, its #2699 holding.
  • 173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.